NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.arcutis.comThe patent US12042487 related to ZORYVE, a PDE-4 inhibitor drug developed by Arcutis Biotherapeutics Inc, expires today. This patent covers a method to improve the pharmacokinetics of a PDE-4 inhibitor formulation, specifically aimed at reducing gastrointestinal side effects and enhancing patient compliance by managing the spike in Cmax through the combination of the inhibitor with phosphate ester surfactants.
Patent ExpiryThe patent US9907788 for ZORYVE, assigned to Arcutis Biotherapeutics Inc, is set to expire on June 7, 2037. ZORYVE is a topical treatment that leverages a formulation to improve the bioavailability and efficacy of roflumilast, a phosphodiesterase 4 inhibitor used to treat certain dermatological conditions. The patent's expiration could allow for increased market competition and potential generic versions of the drug, impacting Arcutis's financial landscape.
Patent ExpirationPatent US11129818 for ZORYVE, a topical formulation of roflumilast, will expire on August 25, 2037, potentially impacting the product's exclusivity and market position. The patent covers improved delivery methods and a longer plasma half-life for the therapeutic, which is significant for treatment effectiveness. As patent expiration may lead to generic competition, this could materially affect Arcutis Biotherapeutics Inc.'s revenues from ZORYVE once exclusivity ends.
Patent ExpirationThe expiration of patent US11707454 for ZORYVE, a topical treatment containing roflumilast, is set for December 3, 2041. This patent covers the use of roflumilast for treating fungal infections and conditions such as seborrheic dermatitis and various types of tinea infections. The expiration may allow for increased competition in the antifungal market, potentially impacting Arcutis Biotherapeutics Inc's market position as alternatives become available.
patent